Press Releases

Year

Jan 24, 2019

Wave Life Sciences Prices $150 Million Public Offering of Ordinary Shares

CAMBRIDGE, Mass. , Jan. 24, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a genetic medicines company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, announced today the pricing of its previously announced underwritten

Jan 23, 2019

Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares

CAMBRIDGE, Mass. , Jan. 23, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a genetic medicines company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, announced today that it has commenced an underwritten public offering of

Jan 03, 2019

Wave Life Sciences Duchenne Muscular Dystrophy Clinical Trial Selected for FDA Complex Innovative Trial Designs Pilot Program

Suvodirsen (WVE-210201) Phase 2/3 trial chosen in inaugural round of pilot program FDA pilot program is a 21 st Century Cures Act initiative CAMBRIDGE, Mass. , Jan. 03, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ: WVE), a biotechnology company focused on delivering transformational